U.S. market Closed. Opens in 9 hours 11 minutes

SVRA | Savara Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 3.21 - 3.45
52 Week Range 2.8150 - 5.70
Beta 0.70
Implied Volatility 148.28%
IV Rank 15.45%
Day's Volume 2,861,626
Average Volume 1,341,407
Shares Outstanding 171,619,000
Market Cap 567,200,795
Sector Healthcare
Industry Biotechnology
IPO Date 2017-04-28
Valuation
Profitability
Growth
Health
P/E Ratio -7.69
Forward P/E Ratio N/A
EPS -0.43
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 37
Country USA
Website SVRA
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
*Chart delayed
Analyzing fundamentals for SVRA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see SVRA Fundamentals page.

Watching at SVRA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on SVRA Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙